Loading...
•
Dec 31, 2022
Cullinan Oncology Q4 2022 Earnings Report
Cullinan Oncology reported fourth quarter and full year 2022 financial results and provided a corporate update.
Key Takeaways
Cullinan Oncology reported a net loss of $27.1 million for the fourth quarter of 2022, with cash and investments totaling $550.1 million as of December 31, 2022, which provides runway into 2026.
Initiated pivotal study of zipalertinib in collaboration with Taiho Oncology in Q4 2022.
Expanded clinical stage portfolio through licensing of U.S. rights to CLN-418.
Received FDA clearance of IND application for CLN-978; submitted IND application for CLN-617.
Initial clinical data updates for CLN-049 and CLN-619 on track for mid-2023.
Cullinan Oncology
Cullinan Oncology
Forward Guidance
Cullinan expects its cash resources to provide runway into 2026 based on its current operating plan.